| Name | Title | Contact Details |
|---|
At Draper` we believe exciting things happen when new capabilities are imagined and created. Whether formulating a concept and developing each component to achieve a field-ready prototype or combining existing technologies in new ways` Draper engineers apply multidisciplinary approaches that deliver new capabilities to customers. As a not-for-profit research and development company` Draper focuses on the design` development and deployment of advanced technological solutions for the world’s most challenging and important problems. We provide engineering services directly to government` industry` and academia; work on teams as prime contractor or subcontractor; and participate as a collaborator in consortia. We provide unbiased assessments of technology or systems designed or recommended by other organizations — custom designed` as well as commercial-off-the-shelf. Draper is a recognized world leader in both Positioning` Navigation and Timing and Microsystems` with additional expertise in Precision Instrumentation` Fault-Tolerant Systems` Secure and Assured Systems` Autonomous Systems` Image and Data Analytics` Human Systems Technology` Materials Engineering and Microfabrication` and Biomedical Solutions. With a strong commitment to deliver working solutions` we apply ourselves to a variety of domains from space to undersea—and many areas in between. We build working prototypes for field testing` accelerating design iterations; and we complete small production runs. We work with commercial partners to transition our technology to commercial large-volume production` including licensing intellectual property` and provide life-cycle support` including technology refresh.
Stowers Resource Management is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.
Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pro Med Molded Products Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.